Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review

The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series

(2020) Naomi Serling-Boyd et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

(2020) Philip Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase

(2020) Enriqueta Vallejo-Yagüe et al.   DRUG SAFETY

Age-based (

(2020) Kevin L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients

(2020) Gustavo Citera et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy

(2019) Yi-Ming Chen et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

(2019) Wenhui Xie et al.   ANNALS OF THE RHEUMATIC DISEASES

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

(2019) Katie Bechman et al.   RHEUMATOLOGY

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis

(2019) Christina Charles‐Schoeman et al.   Arthritis & Rheumatology

Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years

(2019) Janet Pope et al.   RHEUMATOLOGY

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts

(2019) Mueller et al.   Journal of Clinical Medicine

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors

(2018) Anissa Roger et al.   ANNALS OF THE RHEUMATIC DISEASES

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review

(2018) Michael Nurmohamed et al.   DRUG SAFETY

A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population

(2018) Alan J. Kivitz et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program

(2018) Xavier Mariette et al.   ARTHRITIS CARE & RESEARCH

Long term outcomes following achievement of clinically inactive disease in juvenile idiopathic arthritis: the importance of definition

(2018) Stephanie JW Shoop-Worrall et al.   Arthritis & Rheumatology

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab

(2018) Joel M. Kremer et al.   Arthritis & Rheumatology

Editorial: Magnetic Resonance Imaging Signals in the Sacroiliac Joints of Healthy Athletes: Refining Disease Thresholds and Treatment Strategies in Axial Spondyloarthritis

(2018) Christopher Ritchlin   Arthritis & Rheumatology

Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate

(2018) Jeffrey R Curtis et al.   ARTHRITIS CARE & RESEARCH

Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients

(2018) Rishi J. Desai et al.   Arthritis & Rheumatology

Evaluation of the Short‐, Mid‐, and Long‐term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis

(2018) Ronald van Vollenhoven et al.   Arthritis & Rheumatology

Preventive therapy for latent tuberculosis infection—the promise and the challenges

(2017) G.J. Fox et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

(2017) Roy Fleischmann et al.   LANCET

Malignancy and Janus Kinase Inhibition

(2017) Padmapriya Sivaraman et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study

(2017) Kensuke Kume et al.   RHEUMATOLOGY INTERNATIONAL

A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis

(2017) Yong Chen et al.   Scientific Reports

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

(2017) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

(2016) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

(2016) Vibeke Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib

(2016) Jeffrey R. Curtis et al.   CLINICAL RHEUMATOLOGY

Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis

(2016) Maria-Cecilia Vieira et al.   CLINICAL THERAPEUTICS

Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials

(2016) Priyanka Vashisht et al.   ARTHRITIS CARE & RESEARCH

Immediate Administration of Intraarticular Triamcinolone Acetonide After Joint Injury Modulates Molecular Outcomes Associated With Early Synovitis

(2016) Jakob T. Sieker et al.   Arthritis & Rheumatology

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

(2016) Fenglong Xie et al.   Arthritis & Rheumatology

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

(2015) K L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

(2015) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled tri

(2015) Young Ho Lee et al.   International Journal of Rheumatic Diseases

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

(2015) Vibeke Strand et al.   ARTHRITIS RESEARCH & THERAPY

FRI0185 In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50 mg or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-arm, double-blind study

(2014) R. V. Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Population-Based Study of the Epidemiology of Herpes Zoster in Korea

(2014) You Jeong Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

(2014) Alejandro Souto et al.   RHEUMATOLOGY

Systematic review of incidence and complications of herpes zoster: towards a global perspective

(2014) K. Kawai et al.   BMJ Open

Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis

(2014) Alejandro Souto et al.   Arthritis & Rheumatology

Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

(2014) Stanley Cohen et al.   Arthritis & Rheumatology

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis

(2011) F. G. Goh et al.   RHEUMATOLOGY